1-4 of 4
Archie G. Prentice, MD
Close
Sort by
Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil
Journal: Blood
Blood (2007) 110 (11): 589.
https://doi.org/10.1182/blood.V110.11.589.589
Published: 2007
Journal Articles

Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.

Alan K. Burnett, MD, Donald Milligan, MD, Archie G. Prentice, MD, Anthony H. Goldstone, MD, Mary F. McMullin, MD, Keith Wheatley, PhD
Journal: Blood
Blood (2004) 104 (11): 872.
https://doi.org/10.1182/blood.V104.11.872.872
Published: 2004
Journal Articles

The Impact of Transplant in AML in 2nd CR: A Prospective Study of 741 in the MRC AML 10 and 12 Trials.

Alan K. Burnett, MD, Robert K. Hills, PhD, Anthony H. Goldstone, MD, Donald Milligan, MD, Archie G. Prentice, MD, Ian Hann, MD, David Webb, MD, Brenda Gibson, MD, Keith Wheatley, PhD
Journal: Blood
Blood (2004) 104 (11): 620.
https://doi.org/10.1182/blood.V104.11.620.620
Published: 2004
Journal Articles

Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.

Alan K. Burnett, MD, Donald Milligan, MD, Robert K. Hills, PhD, Anthony H. Goldstone, MD, Archie G. Prentice, MD, Keith Wheatley, PhD, David C. Webb, MD, Brenda Gibson, MD
Journal: Blood
Blood (2004) 104 (11): 1794.
https://doi.org/10.1182/blood.V104.11.1794.1794
Published: 2004